Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
Abstract
For diffuse large B‐cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3‐year probabilities of non‐relapse mortality, progression/relapse, progression‐free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status (KPS) HCT to alloHCT interval OS on multivariate analysis included KPSPFS, including KPSHCT to alloHCT interval HCT (5 points). This CIBMTR prognostic model classified patients into four groups: low‐risk (0 points), intermediate‐risk (2‐5 points), high‐risk (6‐9 points) or very high‐risk (11 points), predicting 3‐year PFS of 40, 32, 11 and 6%, respectively, with 3‐year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long‐term survival with alloHCT after a failed prior autoHCT.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 15, 2016
- Source ID
- 10.1111/bjh.14046
Entities
People
- Alyssa Digilio
- Andy Chen
- Anita D'Souza
- Anna Sureda
- Attaphol Pawarode
- Cesar Freytes
- David J. Inwards
- Ernesto Ayala
- Hillard M Lazarus
- Jonathan E. Brammer
- Kwang W. Ahn
- Mark Hertzberg
- Mehdi Hamadani
- Miguel‐angel Perales
- Mitchell S Cairo
- Mohamed A. Kharfan‐dabaja
- Nishitha Reddy
- Qaiser Bashir
- Rammurti T. Kamble
- Sachiko Seo
- Samantha Jaglowski
- Saurabh Chhabra
- Siddhartha Ganguly
- Sonali M Smith
- Sunita Nathan
- Tara M. Graff
- Timothy S. Fenske
- Ulrike Bacher
- Umar Farooq
- Yi‐bin Chen
Organizations
- Baylor College of Medicine
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- Froedtert Hospital
- GSK
- Genzyme
- H. Lee Moffitt Cancer Center & Research Institute
- Health Research
- Health Resources and Services Administration
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Massachusetts General Hospital
- Mayo Clinic
- Medical College of Wisconsin
- Medical University of South Carolina
- Memorial Sloan Kettering Cancer Center
- Merck & Co.
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- New York Medical College
- Office of Naval Research
- Ohio State University
- Onyx Pharmaceuticals
- Oregon Health & Science University
- Otsuka (United States)
- Prince of Wales Hospital, Sydney
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Rush University
- St. Baldrick's Foundation
- StemCyte
- Tarix Orphan (United States)
- University of Chicago
- University of Iowa
- University of Kansas
- University of Michigan
- University of Minnesota
- University of Texas at Austin
- University of Utah
- Vanderbilt University